We applied this new imaging approach to patient-derived melanoma xenografts treated with CDC42-effector interaction inhibitors or other standard-of-care melanoma therapies (BRAF inhibitors) and demonstrated that both types of drugs had similar tumor-suppressive effects and altered patterns of vessel arborization in tumors. Here, BRAF is linked to melanoma.